PATIENT INFORMATION LEAFLET FOR GRIPPOL® PLUS MEDICINAL PRODUCT

The vaccine induces a high level of specific immunity against influenza. The protective effect after vaccination usually comes after 8-12 days and lasts up to 12 months, including in elderly people. Antibody protective titers to influenza viruses after vaccination of individuals of different ages are detected in 75-95% of those vaccinated.

The inclusion of the Polyoxidonium® immunomodulator, which has a broad spectrum of immunopharmacological action, in the vaccine preparation provides increased immunogenicity and stability of antigens, allows increasing immunological memory, significantly reducing the vaccine dose of antigens, increasing resistance of the body to other infections through the correction of immune status.

Specific influenza prevention in children from 6 months of age, adolescents, and adults without age restriction.

Persons at high risk of complications if they contract the flu:

• over 60 years old;
• preschool children, schoolchildren;
• Adults and children with frequent acute respiratory infections, chronic somatic diseases, including: diseases and malformations of the central nervous, cardiovascular and bronchopulmonary systems, bronchial asthma, chronic kidney disease, diabetes mellitus, metabolic diseases, autoimmune diseases, allergic diseases (except chicken protein allergy); chronic anemia, congenital or acquired immune deficiency, HIV infected;

Persons who are at high risk of contracting the flu or infecting other people due to their profession:
Health care workers, employees of educational institutions, social services, transport, trade, police, military personnel, etc.

Vaccinations take place annually during the autumn-winter period. Vaccination is possible at the beginning of the flu epidemic.

Children over 3 years of age, adolescents, and adults get the vaccine intramuscularly or deep subcutaneously into the upper third of the outer surface of the upper arm (deltoid muscle), infants get it intramuscularly into the anterolateral surface of the thigh.

For children aged 6 to 35 months inclusive - 0.25 ml twice with an interval of 3 to 4 weeks.

Children over 36 months old and adults are administered the vaccine once at a dose of 0.5 ml

Influenza-negative and unvaccinated children can be vaccinated twice at intervals of 3-4 weeks.

Immunocompromised patients receiving immunosuppressive therapy may be administered the vaccine twice, 0.5 ml at an interval of 3-4 weeks.

The vaccine should be brought to room temperature and shaken well before use. Remove the protective cap from the needle and deflate the syringe by holding it upright with the needle up and slowly pushing down the piston.

To immunize children for whom 0.25 ml (1/2 dose) of the vaccine is indicated, remove half of the syringe content by pushing the plunger down to the special mark on the syringe body or to the red mark on the edge of the label and inject the remaining 0.25 ml.

Open the ampoules and vials and carry out the vaccination procedure in strict compliance with aseptic and antiseptic rules: before opening the ampoule knife, the neck of the ampoule or the stopper of the vial is wiped with cotton wool moistened with 70% ethyl alcohol, the ampoule is opened or the rubber stopper of the vial is pierced with a needle, vaccine is filled into a single-use syringe, and excess air is removed from the syringe. Wipe the skin at the injection site with alcohol. Do not store the product in an open ampoule or vial.